论文部分内容阅读
采用小鼠肝癌H22移植性肿瘤模型,考察不同给药途径和剂量下,毛萼乙素纳米混悬剂的抗肿瘤作用及毒性。在适宜的给药剂量下,毛萼乙素纳米混悬剂经静脉注射、腹腔注射和灌胃3种途径给药均可抑制小鼠肝癌H22移植瘤的生长,并呈现明确的量效关系,但其毒性也随着剂量的增加而明显增大。在10 mg/kg的剂量下,腹腔注射的抑瘤作用优于静脉注射;但该途径给药产生的毒性也比静脉注射大。灌胃给药的抑瘤作用最弱,且高剂量时会产生严重的胃肠道不良反应。
The mouse hepatocellular carcinoma H22 transplanted tumor model was used to investigate the anti-tumor effect and toxicity of Eriobucaceae nano-suspension under different administration routes and doses. In the appropriate dose, Eriobetin nanosuspension can inhibit the growth of H22 xenografts of mice hepatoma by intravenous injection, intraperitoneal injection and gavage administration, and showed a clear dose-effect relationship, But its toxicity also increased with the increase of dose obviously. At the dose of 10 mg / kg, intraperitoneal injection had better anti-tumor effect than intravenous injection; however, the route of administration was also more toxic than intravenous injection. Gavage administration of the weakest anti-tumor effect, and high doses will produce serious gastrointestinal adverse reactions.